Evidence map›Paper›PMID 35079256›Full record

ArticleJournal of contemporary brachytherapy2021

Is adaptive treatment planning for single-channel vaginal brachytherapy necessary?

Jan-Erik Palmgren, Jan Seppälä, Maarit Anttila

Abstract read
In one paragraph

Article in Journal of contemporary brachytherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jan-Erik PalmgrenRadiotherapy Department of the Center of Oncology, Kuopio University Hospital, Finland.
Jan SeppäläRadiotherapy Department of the Center of Oncology, Kuopio University Hospital, Finland.
Maarit AnttilaDepartment of Obstetrics and Gynecology, Kuopio University Hospital, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn vaginal cuff brachytherapy, only limited information is available about the need for individualized treatment planning or imaging. Treatment planning is still performed mostly with no contouring target volume or organs at risk and with standard plan approach. Dose prescription, fractionation, and treatment planning practices vary from site to site. Without imaging, dose must be prescribed in terms of fixed distances from a known reference, such as the applicator surface. Because of different anatomies of patients, this might lead to under-dosing of target and unnecessarily high-doses delivered to adjacent organs. Also, reliable recording of dose delivered is difficult. These various uncertainties related to standard planning and lack of imaging indicate a clear need for finding an optimal method of dose planning for vaginal cuff brachytherapy. MATERIAL AND

methodsA study was conducted, in which 100 vaginal cuff brachytherapy patients' computed tomography (CT) images with applicator in situ were retrospectively analyzed to investigate target-area coverage and critical-organ doses. In addition, 28 patients' plans were re-planned with different planning approaches, to evaluate an optimal dose-planning strategy. From treatment plans, target coverage and organs-at-risk doses were assessed. RESULTS AND

conclusionsThe analysis showed that, in order to cover distal part of the vaginal cuff, dose prescription should be a 10 mm from the tip of the applicator. Individualized image-based planning is recommended at least for first fraction. This would yield lower doses to the bladder. Rectum and sigmoid doses are not significantly affected by planning approach.

Indexed as

brachytherapyendometrial cancerimage-based brachytherapy planningvaginal cuff brachytherapy

Identifiers

PMID35079256
PMCPMC8782068

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.